Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Int J Circumpolar Health ; 76(1): 1309504, 2017.
Article in English | MEDLINE | ID: mdl-28467237

ABSTRACT

BACKGROUND: In 2010, Greenland introduced the 13-valent pneumococcal conjugate vaccine (Prevnar 13®- PCV-13) in the childhood immunisation program. The authors aimed to evaluate the impact of PCV-13 on nasopharyngeal carriage of bacteria frequently associated with respiratory infections in children. METHOD: In 2013 a cross-sectional population-based study of nasopharyngeal carriage was conducted among Greenlandic children aged 0-6 years and results were compared with an equivalent study from 2011. Nasopharyngeal swab samples were tested for Streptococcus pneumoniae, non-typeable Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus. Pneumococcal serotyping was performed by Quellung reaction and serotype-specific antisera. Statistical analysis included logistic regression models, adjusting for known risk factors. RESULT: A total of 377 nasopharyngeal samples were collected. Overall carriage rate of S. pneumoniae remained unchanged from 2011 to 2013 (51% and 56%, p=0.13), but significant serotype shifts were observed among both vaccinated and unvaccinated children with marked reductions in carriage of vaccine-type pneumococci, counterbalanced by increasing carriage of non-vaccine types. Carriage rate of S. aureus decreased significantly among vaccinated children whereas that of M. catarrhalis increased. CONCLUSION: PCV-13 introduction in Greenland is associated with significant changes in nasopharyngeal bacterial carriage. Continued surveillance is warranted to clarify whether these changes are persistent, and affect the pattern of respiratory and invasive diseases in Greenland.


Subject(s)
Carrier State/microbiology , Inuit , Nasopharynx/microbiology , Pneumococcal Vaccines/administration & dosage , Respiratory Tract Infections/microbiology , Arctic Regions/epidemiology , Child , Child, Preschool , Cross-Sectional Studies , Female , Greenland/epidemiology , Haemophilus influenzae/isolation & purification , Humans , Infant , Male , Moraxella catarrhalis/isolation & purification , Staphylococcus aureus/isolation & purification , Streptococcus pneumoniae/isolation & purification
2.
Ugeskr Laeger ; 167(32): 2903-4, 2005 Aug 08.
Article in Danish | MEDLINE | ID: mdl-16109199

ABSTRACT

Psoriasis is a chronic, inflammatory skin disorder that is induced and aggravated by a number of endogenous and exogenous factors. Traditionally lithium, beta blockers, NSAIDs, ACE inhibitors and antimalarials have been associated with psoriasis, but interferon can also be a triggering factor. We present two patients with multiple sclerosis who suffered from activation of psoriasis in relation to interferon-beta treatment. In one of the patients, psoriasiform injection site lesions persisted six years after termination of the interferon treatment.


Subject(s)
Adjuvants, Immunologic/adverse effects , Interferon-beta/adverse effects , Psoriasis/chemically induced , Adjuvants, Immunologic/administration & dosage , Adult , Female , Humans , Injections, Subcutaneous , Interferon-beta/administration & dosage , Male , Multiple Sclerosis/drug therapy , Multiple Sclerosis/pathology , Psoriasis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...